Current and Future Management Strategies for Relapsed or Progressive Hepatoblastoma

Venkatramani, Rajkumar; Furman, Wayne L.; Fuchs, Joerg; Warmann, Steven W.; Malogolowkin, Marcio H.

doi:10.2165/11597740-000000000-00000

Cited by 23 publications

(14 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor recurrence is an issue that must be addressed in cases of advanced HB. Several risk factors for tumor recurrence have been evaluated in previous studies, including nonanatomic resection, the AFP level at the time of the diagnosis, the magnitude of the decline in the AFP level following NAC, the presence of extrahepatic lesions, the tumor histological characteristics, the PRETEXT staging, vascular invasion, the tumor size, and the extent of tumor necrosis . With regard to surgical techniques, it is known that anatomic resection for liver tumors, like HB and hepatocellular carcinoma, have a more positive impact on the patient survival than nonanatomic resection and in the present study, anatomic resection was performed in all patients with tumors resected by LR .…”

Section: Discussionmentioning

confidence: 60%

Surgical treatment strategy for advanced hepatoblastoma: Resection versus transplantation

Uchida

Sakamoto

Sasaki

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 60%

Surgical treatment strategy for advanced hepatoblastoma: Resection versus transplantation

Uchida

Sakamoto

Sasaki

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Due to its risks of ototoxicity and nephrotoxicity, cisplatin was omitted in our treatment plan in order to prevent further hearing loss in a significantly developmentally delayed child with known mild sensorineural hearing loss. Doxorubicin is considered the second most active chemotherapeutic agent against hepatoblastoma [Venkatramani et al, ]. Given the child's normal baseline cardiac structure and function, she was treated with doxorubicin (60 mg/m 2 /course) for four courses similar to the previous treatment recommended for Stage I pure fetal hepatoblastoma [Ortega et al, ].…”

Section: Discussionmentioning

confidence: 99%

Hepatoblastoma in a 15‐month‐old female with trisomy 13

Shah

Tran

Randolph

et al. 2013

American J of Med Genetics Pt A

Self Cite

View full text Add to dashboard Cite

Trisomy 13 (T13) is a rare autosomal aneuploidy. Greater than 90% of patients die during the first year of life. Malignancies reported in association with T13 include two cases of Wilms tumor and one case of pilocytic astrocytoma. There is no previous report of hepatoblastoma in patients with T13. We report a unique case of hepatoblastoma in a 15-month-old female with constitutional T13. Our patient was born at 38 weeks gestation and was noted to have phenotypic features consistent with T13. Genetic testing confirmed an abnormal karyotype of 47,XX,+13 in all cells. At fifteen months of age she was noted to have a right hepatic lobe mass on a routine follow-up renal ultrasound for hydronephrosis. Serum alpha-fetoprotein level was 55,300 ng/ml. Staging work-up revealed the absence of metastases. She underwent a complete surgical resection with right hepatic lobectomy. Histopathology was consistent with hepatoblastoma, mixed epithelial and mesenchymal type. She had a protracted postoperative course complicated by Enterobacter aerogenes urosepsis, a significant biloma, chronic pancreatitis, and apneic episodes of uncertain etiology. She received four courses of doxorubicin monotherapy without any severe or unexpected toxicity. She continues to be in remission 8 months following diagnosis. This is the first reported case of hepatoblastoma in a child with constitutional T13. This may represent a non-random association, as somatic trisomy of chromosome 13 in hepatoblastoma tumors has been previously described in the literature. Prolonged survival may have allowed for hepatoblastoma to present in our patient.

show abstract

“…Hepatoblastoma cells have shown gain of 2q, 1q, Xp, and Xq; loss of 4q, 2q, and 1q; and loss of heterozygosity of insulin growth factor 2 (5). Subtypes with increased Notch expression are of the fetal subtype and tend to have a better prognosis.…”

Section: Resultsmentioning

confidence: 99%

“…Despite these clinical advancements, the more aggressive forms of hepatoblastoma remain difficult to treat. Current treatments for aggressive forms of hepatoblastoma include doxorubicin, irinotecan (clinical trials), hepatic artery chemoembolization in addition to chemotherapy agents, as well as liver transplantation or partial resection with neoadjuvant chemotherapy (5). …”

Section: Introductionmentioning

confidence: 99%

Hepatoblastoma: A Need for Cell Lines and Tissue Banks to Develop Targeted Drug Therapies

et al. 2016

View full text Add to dashboard Cite

Limited research exists regarding the most aggressive forms of hepatoblastoma. Cell lines of the rare subtypes of hepatoblastoma with poor prognosis are not only difficult to attain but also challenging to characterize histologically. A community-driven approach to educating parents and families, regarding the need for donated tissue, is necessary for scientists to have access to resources for murine models and drug discovery. Herein, we describe the currently available resources, existing gaps in research, and the path to move forward for uniform cure of hepatoblastoma.

show abstract

Current and Future Management Strategies for Relapsed or Progressive Hepatoblastoma

Cited by 23 publications

References 125 publications

Surgical treatment strategy for advanced hepatoblastoma: Resection versus transplantation

Surgical treatment strategy for advanced hepatoblastoma: Resection versus transplantation

Hepatoblastoma in a 15‐month‐old female with trisomy 13

Hepatoblastoma: A Need for Cell Lines and Tissue Banks to Develop Targeted Drug Therapies

Contact Info

Product

Resources

About